%0 Journal Article
%A Witzens-Harig, Mathias
%A Benner, Axel
%A McClanahan, Fabienne
%A Klemmer, Jennifer
%A Brandt, Julia
%A Brants, Elke
%A Rieger, Michael
%A Meissner, Julia
%A Hensel, Manfred
%A Neben, Kai
%A Dreger, Peter
%A Lengfelder, Eva
%A Schmidt-Wolf, Ingo
%A Krämer, Alwin
%A Ho, Anthony D
%T Rituximab maintenance improves survival in male patients with diffuse large B-cell lymphoma. Results of the HD2002 prospective multicentre randomized phase III trial.
%J British journal of haematology
%V 171
%N 5
%@ 0007-1048
%C Oxford [u.a.]
%I Wiley-Blackwell55962
%M DKFZ-2017-03825
%P 710 - 719
%D 2015
%X In the multicentre prospective randomized HD2002 trial, rituximab maintenance therapy (375 mg/m(2) every 3 months for 2 years) versus observation was evaluated for CD20(+) B-cell lymphoma. Out of 321 patients [161 randomized to the treatment group (TG), 160 to the observation group (OG)], 295 data sets were evaluable for statistical analysis. Estimated 5-year relapse-free survival (RFS) was 81
%K Antineoplastic Agents (NLM Chemicals)
%K Rituximab (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:26449739
%R 10.1111/bjh.13652
%U https://inrepo02.dkfz.de/record/127803